MAP2K7 and melanoma: We performed an in vitro drug screen to assess the dose–response of 43 melanoma cell lines treated with the type 1.5 “first-generation” RAF inhibitor Vemurafenib [39] and the type 2 “panRAF” inhibitor Belvarafenib combined with the allosteric MEK inhibitor Cobimetinib.